Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ectopic acromegaly.

G Faglia1, M Arosio, N Bazzoni

  • 1Institute of Endocrine Sciences, University of Milan, Ospedale Maggiore, IRCCS, Italy.

Endocrinology and Metabolism Clinics of North America
|September 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-time investigation of an influenza A(H3N2) virus outbreak in a refugee community, November 2022.

Public health·2024
Same author

Recurrence in acromegaly: two tertiary centers experience and review of the literature.

Journal of endocrinological investigation·2024
Same author

Disease control of acromegaly does not prevent excess mortality in the long term: results of a nationwide survey in Italy.

Journal of endocrinological investigation·2024
Same author

Indication to dynamic and invasive testing in Cushing's disease according to different neuroradiological findings.

Journal of endocrinological investigation·2021
Same author

Influence of biochemical diagnosis of growth hormone deficiency on replacement therapy response and retesting results at adult height.

Scientific reports·2021
Same author

Spine Bone Texture Assessed by Trabecular Bone Score in Active and Controlled Acromegaly: A Prospective Study.

Journal of the Endocrine Society·2021
Same journal

Navigating Adrenal Disease: A Comprehensive, Practical Guide for the Clinician.

Endocrinology and metabolism clinics of North America·2026
Same journal

Adrenal Disorders in Pregnancy.

Endocrinology and metabolism clinics of North America·2026
Same journal

Diagnosis and Management of Adrenocortical Carcinoma.

Endocrinology and metabolism clinics of North America·2026
Same journal

Pheochromocytomas and Paragangliomas.

Endocrinology and metabolism clinics of North America·2026
Same journal

Hereditary Conditions Associated with Adrenocortical Carcinoma, Pheochromocytoma, and Other Adrenal Tumors: Genetic Testing and Management Recommendations.

Endocrinology and metabolism clinics of North America·2026
Same journal

Primary Bilateral Macronodular Adrenal Hyperplasia.

Endocrinology and metabolism clinics of North America·2026
See all related articles

Ectopic acromegaly, caused by rare hormone-producing tumors, requires early recognition for proper treatment. Measuring growth hormone-releasing hormone (GHRH) aids diagnosis, with octreotide offering therapeutic benefits.

Area of Science:

  • Endocrinology
  • Oncology
  • Medical Diagnostics

Background:

  • Ectopic acromegaly is a rare condition (<1% of acromegaly cases) resulting from tumors producing growth hormone-releasing hormone (GHRH) or growth hormone (GH).
  • Early recognition is crucial as acromegaly can indicate aggressive tumors requiring distinct therapeutic strategies.
  • Most cases involve GHRH-producing tumors (extra-/intracranial), while rare instances stem from ectopic GH-secreting tumors.

Purpose of the Study:

  • To highlight the clinical importance of recognizing ectopic acromegaly.
  • To discuss diagnostic approaches, including routine GHRH evaluation and imaging techniques.
  • To outline therapeutic strategies for ectopic acromegaly.

Main Methods:

  • Routine evaluation of circulating GHRH levels in acromegalic patients.

Related Experiment Videos

  • Plasma GHRH level thresholds (>0.3 ng/mL) for diagnosing GHRH-producing tumors.
  • Utilizing whole-body scintiscan with labeled octreotide for tumor localization.

    • Main Results:

    • Plasma GHRH levels >0.3 ng/mL strongly suggest a GHRH-producing tumor (e.g., bronchial or pancreatic carcinoid).
    • Suppressed GHRH levels may indicate an ectopic GH-producing tumor.
    • Octreotide scintiscan aids in locating ectopic tumors.

    Conclusions:

    • Routine GHRH measurement is vital for early detection of ectopic acromegaly.
    • Surgical tumor removal is the primary treatment, though often limited by metastases.
    • Long-acting somatostatin analog octreotide is beneficial for GHRH-induced acromegaly, reducing hormone levels and tumor size.